Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Rephasin SAL200 in Persistent S. aureus Bacteremia
NCT03089697Phase 2Terminated
- Sponsor
- iNtRON Biotechnology
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tonabacase in Staphylococcus aureus bacteremia (SAB), sponsored by iNtRON Biotechnology. Started Mar 2017; status: terminated.
02
Drugs
tonabacase
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT03089697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089697.